Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BFR ESS
2024-512629-97-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of anastrozole, exemestane and letrozole in Endometrial Sarcoma (ESS) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Progression-free survival. Planned start Jan 2019; status: authorised.
02
Drugs
anastrozoleexemestaneletrozole
03
Conditions
Endometrial Sarcoma (ESS)
Beyond the preview
Go deeper on 2024-512629-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512629-97-00.